Cargando…

Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP

BACKGROUND: Plasma assays for the detection of Alzheimer’s disease neuropathological changes are receiving ever increasing interest. The concentration of plasma glial fibrillary acidic protein (GFAP) has been suggested as a potential marker of astrocytes or recently, amyloid-β burden, although this...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiotis, Konstantinos, Johansson, Charlotte, Rodriguez-Vieitez, Elena, Ashton, Nicholas J., Blennow, Kaj, Zetterberg, Henrik, Graff, Caroline, Nordberg, Agneta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496408/
https://www.ncbi.nlm.nih.gov/pubmed/37697307
http://dx.doi.org/10.1186/s13024-023-00647-y
_version_ 1785105100152242176
author Chiotis, Konstantinos
Johansson, Charlotte
Rodriguez-Vieitez, Elena
Ashton, Nicholas J.
Blennow, Kaj
Zetterberg, Henrik
Graff, Caroline
Nordberg, Agneta
author_facet Chiotis, Konstantinos
Johansson, Charlotte
Rodriguez-Vieitez, Elena
Ashton, Nicholas J.
Blennow, Kaj
Zetterberg, Henrik
Graff, Caroline
Nordberg, Agneta
author_sort Chiotis, Konstantinos
collection PubMed
description BACKGROUND: Plasma assays for the detection of Alzheimer’s disease neuropathological changes are receiving ever increasing interest. The concentration of plasma glial fibrillary acidic protein (GFAP) has been suggested as a potential marker of astrocytes or recently, amyloid-β burden, although this hypothesis remains unproven. We compared plasma GFAP levels with the astrocyte tracer (11)C-Deuterium-L-Deprenyl ((11)C-DED) in a multi-modal PET design in participants with sporadic and Autosomal Dominant Alzheimer’s disease. METHODS: Twenty-four individuals from families with known Autosomal Dominant Alzheimer’s Disease mutations (mutation carriers = 10; non-carriers = 14) and fifteen patients with sporadic Alzheimer’s disease were included. The individuals underwent PET imaging with (11)C-DED, (11)C-PIB and (18)F-FDG, as markers of reactive astrogliosis, amyloid-β deposition, and glucose metabolism, respectively, and plasma sampling for measuring GFAP concentrations. Twenty-one participants from the Autosomal Dominant Alzheimer’s Disease group underwent follow-up plasma sampling and ten of these participants underwent follow-up PET imaging. RESULTS: In mutation carriers, plasma GFAP levels and (11)C-PIB binding increased, while (11)C-DED binding and (18)F-FDG uptake significantly decreased across the estimated years to symptom onset. Cross-sectionally, plasma GFAP demonstrated a negative correlation with (11)C-DED binding in both mutation carriers and patients with sporadic disease. Plasma GFAP indicated cross-sectionally a significant positive correlation with (11)C-PIB binding and a significant negative correlation with (18)F-FDG in the whole sample. The longitudinal levels of (11)C-DED binding showed a significant negative correlation with longitudinal plasma GFAP concentrations over the follow-up interval. CONCLUSIONS: Plasma GFAP concentration and astrocyte (11)C-DED brain binding levels followed divergent trajectories and may reflect different underlying processes. The strong negative association between plasma GFAP and (11)C-DED binding in Autosomal Dominant and sporadic Alzheimer’s disease brains may indicate that if both are markers of reactive astrogliosis, they may detect different states or subtypes of astrogliosis. Increased (11)C-DED brain binding seems to be an earlier phenomenon in Alzheimer’s disease progression than increased plasma GFAP concentration. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13024-023-00647-y.
format Online
Article
Text
id pubmed-10496408
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104964082023-09-13 Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP Chiotis, Konstantinos Johansson, Charlotte Rodriguez-Vieitez, Elena Ashton, Nicholas J. Blennow, Kaj Zetterberg, Henrik Graff, Caroline Nordberg, Agneta Mol Neurodegener Research Article BACKGROUND: Plasma assays for the detection of Alzheimer’s disease neuropathological changes are receiving ever increasing interest. The concentration of plasma glial fibrillary acidic protein (GFAP) has been suggested as a potential marker of astrocytes or recently, amyloid-β burden, although this hypothesis remains unproven. We compared plasma GFAP levels with the astrocyte tracer (11)C-Deuterium-L-Deprenyl ((11)C-DED) in a multi-modal PET design in participants with sporadic and Autosomal Dominant Alzheimer’s disease. METHODS: Twenty-four individuals from families with known Autosomal Dominant Alzheimer’s Disease mutations (mutation carriers = 10; non-carriers = 14) and fifteen patients with sporadic Alzheimer’s disease were included. The individuals underwent PET imaging with (11)C-DED, (11)C-PIB and (18)F-FDG, as markers of reactive astrogliosis, amyloid-β deposition, and glucose metabolism, respectively, and plasma sampling for measuring GFAP concentrations. Twenty-one participants from the Autosomal Dominant Alzheimer’s Disease group underwent follow-up plasma sampling and ten of these participants underwent follow-up PET imaging. RESULTS: In mutation carriers, plasma GFAP levels and (11)C-PIB binding increased, while (11)C-DED binding and (18)F-FDG uptake significantly decreased across the estimated years to symptom onset. Cross-sectionally, plasma GFAP demonstrated a negative correlation with (11)C-DED binding in both mutation carriers and patients with sporadic disease. Plasma GFAP indicated cross-sectionally a significant positive correlation with (11)C-PIB binding and a significant negative correlation with (18)F-FDG in the whole sample. The longitudinal levels of (11)C-DED binding showed a significant negative correlation with longitudinal plasma GFAP concentrations over the follow-up interval. CONCLUSIONS: Plasma GFAP concentration and astrocyte (11)C-DED brain binding levels followed divergent trajectories and may reflect different underlying processes. The strong negative association between plasma GFAP and (11)C-DED binding in Autosomal Dominant and sporadic Alzheimer’s disease brains may indicate that if both are markers of reactive astrogliosis, they may detect different states or subtypes of astrogliosis. Increased (11)C-DED brain binding seems to be an earlier phenomenon in Alzheimer’s disease progression than increased plasma GFAP concentration. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13024-023-00647-y. BioMed Central 2023-09-12 /pmc/articles/PMC10496408/ /pubmed/37697307 http://dx.doi.org/10.1186/s13024-023-00647-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Chiotis, Konstantinos
Johansson, Charlotte
Rodriguez-Vieitez, Elena
Ashton, Nicholas J.
Blennow, Kaj
Zetterberg, Henrik
Graff, Caroline
Nordberg, Agneta
Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP
title Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP
title_full Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP
title_fullStr Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP
title_full_unstemmed Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP
title_short Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP
title_sort tracking reactive astrogliosis in autosomal dominant and sporadic alzheimer’s disease with multi-modal pet and plasma gfap
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496408/
https://www.ncbi.nlm.nih.gov/pubmed/37697307
http://dx.doi.org/10.1186/s13024-023-00647-y
work_keys_str_mv AT chiotiskonstantinos trackingreactiveastrogliosisinautosomaldominantandsporadicalzheimersdiseasewithmultimodalpetandplasmagfap
AT johanssoncharlotte trackingreactiveastrogliosisinautosomaldominantandsporadicalzheimersdiseasewithmultimodalpetandplasmagfap
AT rodriguezvieitezelena trackingreactiveastrogliosisinautosomaldominantandsporadicalzheimersdiseasewithmultimodalpetandplasmagfap
AT ashtonnicholasj trackingreactiveastrogliosisinautosomaldominantandsporadicalzheimersdiseasewithmultimodalpetandplasmagfap
AT blennowkaj trackingreactiveastrogliosisinautosomaldominantandsporadicalzheimersdiseasewithmultimodalpetandplasmagfap
AT zetterberghenrik trackingreactiveastrogliosisinautosomaldominantandsporadicalzheimersdiseasewithmultimodalpetandplasmagfap
AT graffcaroline trackingreactiveastrogliosisinautosomaldominantandsporadicalzheimersdiseasewithmultimodalpetandplasmagfap
AT nordbergagneta trackingreactiveastrogliosisinautosomaldominantandsporadicalzheimersdiseasewithmultimodalpetandplasmagfap